(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/150731 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) *A61K 35/17* (2015.01)
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/US2022/011877

(22) International Filing Date:
10 January 2022 (10.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/136,202	11 January 2021 (11.01.2021)	US
63/150,498	17 February 2021 (17.02.2021)	US
63/168,235	30 March 2021 (30.03.2021)	US
63/211,947	17 June 2021 (17.06.2021)	US

(71) Applicant: **SANA BIOTECHNOLOGY, INC.** [US/US]; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US).

(72) Inventors: **SHAH, Jagesh Vijaykumar**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **BANDORO, Christopher**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **CRUITE, Patricia**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **ELPEK, Kutlu**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **EMMANUEL, Akinola Olumide**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **MACKENZIE, Lauren Pepper**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). **TRUDEAU, Kyle Marvin**; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US).

(74) Agent: **RICE, Rachel** et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: USE OF CD8-TARGETED VIRAL VECTORS

FIG. 1A





(57) Abstract: Provided herein are methods of transducing resting or non-activated T cells using CD8-targeted viral vectors.

[Continued on next page]

WO 2022/150731 A1

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*